| XU Yong-xiang,LI Xiang-yong,SUN Kai.Clinical verification of Neptune 3D-RTPS-A treatment planning system compared to Prowess TPS[J].Chinese Journal of Radiological Medicine and Protection,2011,31(4):465-467 |
| Clinical verification of Neptune 3D-RTPS-A treatment planning system compared to Prowess TPS |
| Received:January 04, 2011 |
| DOI：10.3760/cma.j.issn.0254-5098.2011.04.023 |
| KeyWords:Treatment planning system(TPS) Clinical verification Validity Safety |
| FundProject: |
| Author Name | Affiliation | | XU Yong-xiang | Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
| | LI Xiang-yong | Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
| | SUN Kai | Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
|
|
| Hits: 4120 |
| Download times: 3581 |
| Abstract:: |
| Objective To investigate the safety and validity of Neptune 3D-RTPS-A treatment planning system compared to Prowess TPS. Methods A total of 30 clinical tumor cases with radiotherapy planning on Prowess TPS from September 2009 to May 2010 were used. The contours, organs at risk and target volumes in Prowess TPS were transported into Neptune TPS, the same parameters setted in the two treatment planning systems. The results of comparison of the two TPS were calculated. Results All cases of clinical treatment planning were completed successfully by Neptune TPS, and the various functions of the design were achieved for fitting tumor conformal radiation therapy.The key parameters on radiation treatment were compared.The results are as follows: the differences of source skin distance (SSD) <0.5%, differences of Monitor Unites <0.5%, the differences of dose at isocenter <2%, the differences of five isodose lines surrounding area <3%, and the mean difference of distances of five isodose lines was 0.43 mm, the differences of the volume of PTV on 90% isodose line<2%, and the differences in V30 of organs at risk<3%. Conclusions Neptune TPS could be qualified for clinical validity and safety by clinical verification. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
